CSPC Pharmaceutical Group: Total revenue in 2025 is 26.006 billion yuan, with a cumulative external licensing amount of $28.21 billion.

On March 25, CSPC Pharmaceutical Group announced its full-year results for the fiscal year ending December 31, 2025. The company’s total revenue and its subsidiaries amounted to 26.006 billion yuan, a 10.4% decrease from 29.009 billion yuan in 2024. Additionally, net profit attributable to shareholders was 3.882 billion yuan, down 10.3% year-over-year. Basic earnings per share were 33.98 cents, a 7.8% decline compared to the previous year. Despite the revenue decline, the company increased its final dividend per share to 15 Hong Kong cents, a 50.0% increase from last year.

In the financial review, the proprietary Chinese medicine business revenue was 20.584 billion yuan, a 13.3% decrease year-over-year. Sales in the neurological and anti-tumor sectors fell by 19.0% and 50.0%, respectively. Raw material product revenue slightly increased by 2.1% to 3.657 billion yuan, while functional foods and other businesses grew by 4.5%, reaching 1.765 billion yuan.

The announcement highlighted that several blockbuster products and new indications approved for listing in 2024–2025 continue to drive the group’s growth: Mingfule® as an innovative drug for cerebrovascular diseases has maintained and strengthened the company’s advantages in this field, creating synergy with Enbip® and further consolidating its leading position in cerebrovascular disease treatment; successful market launches of products such as Enshuxing® (Nelan Subevacumab Injection), biosimilar Omalizumab Erelta®, the antidiabetic drug Ploglitazone Tablets, and Meloxicam Nanocrystal Injection have balanced the company’s layout across autoimmune diseases, endocrine metabolism, and oncology, significantly expanding future growth potential.

In 2025, the company received 14 manufacturing approvals and 73 clinical approvals, with five breakthrough therapy designations, many of which are globally patented and highly valuable blockbuster products. The company continues to advance its innovation pipeline, strengthen key core technology research, and leverage two national key laboratories to focus on applied basic research and overcoming common technical challenges. It is actively exploring frontier technologies such as cell therapy and nucleic acid therapy, developing products like the autologous CAR-T candidate SYS6055, tumor therapeutic vaccines, and small nucleic acid drugs, further enhancing its innovative product portfolio and demonstrating strong R&D capabilities. Additionally, in digitalization, the company is actively deepening the application of AI in drug R&D, expanding AI-assisted research platforms to empower innovation, accelerate intelligent transformation, and continuously improve R&D efficiency and results translation.

In business expansion, since the beginning of 2025, the company has completed five external licensing agreements, with a total contract value of $28.21 billion, fully demonstrating the group’s international innovation capability and technological strength. This has significantly enhanced the group’s global reputation and industry influence, laying a solid foundation for expanding overseas markets and deepening international cooperation.

(CSPC Pharmaceutical Group Announcement)

(Editors: Yang Yan, Lin Chen)

Keywords: Healthcare